Medigene, a cancer-focused platform company (FSE: MDG1, Prime Standard) specializing in T cell receptor (TCR)-guided therapies, has announced the filing of a patent with the European Patent Office for a new natural killer (NK) cell-specific TCR construct. This move expands Medigene’s TCR-guided strategy by applying its proprietary 3S (sensitive, specific, and safe) TCRs to NK cells. The patent application significantly broadens Medigene’s intellectual property, extending its therapeutic capabilities and reinforcing its dedication to creating innovative, off-the-shelf cancer immunotherapies.
Medigene’s innovation combines TCR-guided precision with innate NK cell killing. The company has created a unique universal scaffold that enables its 3S TCRs to function in NK cells without the need for CD3 co-expression. This novel NK-TCR system enhances NK cell production and therapeutic potential by efficiently transferring all 3S TCRs into NK cells, thereby simplifying the manufacturing of allogeneic TCR-NK therapies. By removing CD3 dependency, this method overcomes a key obstacle in TCR-based NK cell therapy development, providing a scalable and clinically viable solution that speeds up therapeutic timelines and lowers costs.
According to Selwyn Ho, CEO of Medigene, “This innovative approach furthers our strategy of applying Medigene’s 3S TCRs to new TCR-guided modalities, such as TCR-TCEs and now TCR-NKs, to generate additional value for patients and our shareholders. Expanding our TCR-guided therapies to include NK cells aligns with our commitment to developing off-the-shelf, highly specific, and effective immunotherapies for cancer treatment.”
The global NK cell therapeutics market is growing rapidly, fueled by increasing cancer rates, an aging population, and the demand for innovative immunotherapies. The market, valued at approximately $0.55 billion in 2024, is projected to reach $2.13 billion by 2033 (Source: ). Medigene’s proprietary TCR-NK technology is well-positioned to contribute to this growth with highly specific and scalable NK cell-based therapies.
Medigene is continuously strengthening its intellectual property portfolio by generating new 3S TCRs, developing advanced technologies, and strategically expanding existing patents to additional regions. With over 29 unique patent families worldwide, Medigene protects its proprietary TCR and End-to-End Platform technologies, ensuring a strong competitive position in the immunotherapy field.
— end of press release —
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology platform company focused on the development of T cell receptor (TCR)-guided therapies for the effective elimination of cancer. Its End-to-End Platform produces optimal 3S (sensitive, specific and safe) T cell receptors with unique attributes that can be used in multiple therapeutic approaches, such as off-the-shelf TCR-guided T cell engager (TCR-TCE) therapies (MDG3010 and MDG3020), TCR-natural killer cell (TCR-NK) therapies, and T cell receptor engineered T cell (TCR-T) therapies (MDG1015). For more information, please visit
This press release includes forward-looking statements that reflect Medigene’s opinion as of the release date. Actual results may differ significantly from these statements. Medigene is not obligated to update these forward-looking statements. Medigene® is a registered trademark of Medigene AG and may be owned or licensed in specific locations only.
Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com
If you no longer wish to receive information from Medigene, please notify us via email (). We will then remove your address from our distribution list.
“`
